Printed from https://ideas.repec.org/s/spr/aphecp.html
Content
November 2024, Volume 22, Issue 6
- 767-769 Economic Epidemiology: A Framework to Study Interactions of Epidemics and the Economy
by Aditya Goenka & Lin Liu - 771-781 Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland
by Claire Gorry & Maria Daly & Rosealeen Barrett & Karen Finnigan & Amelia Smith & Stephen Doran & Bernard Duggan & Sarah Clarke & Michael Barry - 783-796 The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates
by Susanne Mayer & Michael Berger & Nataša Perić & Claudia Fischer & Alexander Konnopka & Valentin Brodszky & Silvia M. A. A. Evers & Leona Hakkaart-van Roijen & Mencia Ruiz Guitérrez Colosia & Luis Salvador-Carulla & A-La Park & Joanna Thorn & Lidia García-Pérez & Judit Simon - 797-804 Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges
by Oscar Espinosa & Paul Rodríguez-Lesmes & Giancarlo Romano & Esteban Orozco & Sergio Basto & Diego Ávila & Lorena Mesa & Hernán Enríquez - 805-813 Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance
by Michal Pruski & Susan O’Connell & Laura Knight & Rhys Morris - 815-825 Impact of Government-Funded Health Insurance on Out-of-Pocket Expenditure and Quality of Hospital-Based Care in Indian States of Madhya Pradesh and Maharashtra
by Samir Garg & Kirtti Kumar Bebarta & Narayan Tripathi & Vikash Ranjan Keshri - 827-832 Are Drug Novelty Characteristics Associated With Greater Health Benefits?
by A. Alex Levine & Daniel E. Enright & Katherine A. Clifford & Stacey Kowal & James D. Chambers - 833-847 Financial Literacy and Mental Health: Empirical Evidence from China
by Naijie Guan & Alessandra Guariglia & Patrick Moore & Hareth Al-Janabi - 849-860 Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling
by Kailu Wang & Ho-Man Shum & Carrie Ho-Kwan Yam & Yushan Wu & Eliza Lai-Yi Wong & Eng-Kiong Yeoh - 861-869 The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes
by Ting Zhao & Michelle Tew & Talitha Feenstra & Pieter Baal & Michael Willis & William J. Valentine & Philip M. Clarke & Barnaby Hunt & James Altunkaya & An Tran-Duy & Richard F. Pollock & Samuel J. P. Malkin & Andreas Nilsson & Phil McEwan & Volker Foos & Jose Leal & Elbert S. Huang & Neda Laiteerapong & Mark Lamotte & Harry Smolen & Jianchao Quan & Luís Martins & Mafalda Ramos & Andrew J. Palmer - 871-883 A Contingent Valuation Study for Use in Valuing Public Goods with Health Externalities: The Case of Street Pianos
by Aikaterini Papadopoulou & Helen Mason & Cam Donaldson - 885-896 Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment
by Madhumitha Haridoss & Akhil Sasidharan & Sajith Kumar & Kavitha Rajsekar & Krishnamurthy Venkataraman & Bhavani Shankara Bagepally
September 2024, Volume 22, Issue 5
- 599-607 Cost of Carbon in the Total Cost of Healthcare Procedures: A Methodological Challenge
by Paul-Simon Pugliesi & Laurie Marrauld & Catherine Lejeune - 609-617 A Multi-dimensional Framework of Valued Output for Primary Care in England
by Margherita Neri & Patricia Cubi-Molla & Graham Cookson - 619-628 Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit
by Dominic Muston - 629-652 Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally
by Sabine Vogler & Katharina Habimana & Manuel Alexander Haasis & Stefan Fischer - 653-664 Are Medical Device Characteristics Included in HTA Methods Guidelines and Reports? A Brief Review
by Rituparna Basu & Simon Eggington & Natalie Hallas & Liesl Strachan - 665-684 The Economic Impact of Community Paramedics Within Emergency Medical Services: A Systematic Review
by Matt Wilkinson-Stokes & Michelle Tew & Celene Y. L. Yap & Di Crellin & Marie Gerdtz - 685-700 The Cost-Effectiveness of Primary Prevention Interventions for Skin Cancer: An Updated Systematic Review
by Louisa G. Collins & Ryan Gage & Craig Sinclair & Daniel Lindsay - 701-715 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa
by Pim W. M. Dorst & Simon Pol & Piero Olliaro & Sabine Dittrich & Juvenal Nkeramahame & Maarten J. Postma & Cornelis Boersma & Antoinette D. I. Asselt - 717-724 How Does the New Australian EQ-5D-5L Value Set Impact Utility Scores? Analysis of Data from the Australian Orthopaedic Association National Joint Replacement Registry
by Ilana N. Ackerman & Richard Norman & Ian A. Harris & Kara Cashman & Michelle Lorimer & Stephen Gill & Peter Lewis & Sze-Ee Soh - 725-734 Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand
by Rungroj Krittayaphong & Unchalee Permsuwan - 735-747 Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
by Maryia Zhdanava & Jacqueline Pesa & Porpong Boonmak & Samuel Schwartzbein & Qian Cai & Dominic Pilon & Zia Choudhry & Marie-Hélène Lafeuille & Patrick Lefebvre & Nizar Souayah - 749-765 Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study
by Theodore Laetsch & Jie Zhang & Hongbo Yang & Yanwen Xie & Dudan Zhang & Louis Garrison
July 2024, Volume 22, Issue 4
- 427-433 Health Economics in a World of Uneconomic Growth
by Martin Hensher & Gerry McCartney & Eleanor Ochodo - 435-445 Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study
by Matthew Franklin & Sebastian Hinde & Rachael Maree Hunter & Gerry Richardson & William Whittaker - 447-455 #SharingHEOR: Developing Modern Media for Communication and Dissemination of Health Economics and Outcomes Research
by Davene R. Wright & Mikaela Batista & Tim Wrightson - 457-470 Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis
by Enxue Chang & Haofei Li & Wanji Zheng & Lan Zhou & Yanni Jia & Wen Gu & Yiyin Cao & Xiaoying Zhu & Juan Xu & Bo Liu & Mao You & Kejun Liu & Mingsi Wang & Weidong Huang - 471-483 Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis
by Umenthala Srikanth Reddy - 485-501 Cost of Low-Value Imaging Worldwide: A Systematic Review
by Elin Kjelle & Ingrid Øfsti Brandsæter & Eivind Richter Andersen & Bjørn Morten Hofmann - 503-525 Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment
by Mohsen Ghaffari Darab & Lidia Engel & Dennis Henzler & Michael Lauerer & Eckhard Nagel & Vicki Brown & Cathrine Mihalopoulos - 527-542 A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening
by Stuart J. Wright & Ewan Gray & Gabriel Rogers & Anna Donten & Katherine Payne - 543-554 Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden
by Chiara Malmberg & Magnus Värendh & Patric Berling & Mata Charokopou & Erik Eklund - 555-568 Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China
by Ningxin Ding & Huixuan Zhou & Chen Chen & Hui Chen & Yunfeng Shi - 569-582 Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India
by Jyoti Dixit & Pankaj Malhotra & Nikita Mehra & Anisha Mathew & Lalit Kumar & Ashish Singh & Nidhi Gupta & Manjunath Nookala Krishnamurthy & Partha Sarathi Roy & Amal Chandra Kataki & Sudeep Gupta & Shankar Prinja - 583-598 The Hidden Toll of Psychological Distress in Australian Adults and Its Impact on Health-Related Quality of Life Measured as Health State Utilities
by Muhammad Iftikhar ul Husnain & Mohammad Hajizadeh & Hasnat Ahmad & Rasheda Khanam
May 2024, Volume 22, Issue 3
- 273-281 Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable?
by Jonathan Karnon & Andrew Partington & Jodi Gray & Aubyn Pincombe & Timothy Schultz - 283-296 What Interventions are Cost Effective in Reducing Violence Against Women? A Scoping Review
by Lauren Sheppard & Moosa Alsubhi & Vicki Brown & Ha Le & Kim Robinson & Marj Moodie - 297-313 A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
by Néboa Zozaya & Javier Villaseca & Irene Fernández & Fernando Abdalla & Benito Cadenas-Noreña & Miguel Ángel Calleja & Pedro Gómez-Pajuelo & Jorge Mestre-Ferrándiz & Juan Oliva-Moreno & José Luis Trillo & Álvaro Hidalgo-Vega - 315-329 Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?
by Helen Dakin & Apostolos Tsiachristas - 331-341 Simplified Methods for Modelling Dependent Parameters in Health Economic Evaluations: A Tutorial
by Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Juan David Rios & Andrei Volodin - 343-352 Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective
by Karissa M. Johnston & Ivana F. Audhya & Jessica Dunne & David Feeny & Peter Neumann & Daniel C. Malone & Shelagh M. Szabo & Katherine L. Gooch - 353-362 Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana
by Yizhi Liang & Yuqian Lin & Boshen Jiao - 363-374 The Impact of Raising Alcohol Taxes on Government Tax Revenue: Insights from Five European Countries
by Jakob Manthey & Inese Gobiņa & Laura Isajeva & Jarosław Neneman & Rainer Reile & Mindaugas Štelemėkas & Jürgen Rehm - 375-390 Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA
by Tran T. Doan & David W. Hutton & Davene R. Wright & Lisa A. Prosser - 391-400 Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration
by Takeru Shiroiwa & Takashi Fukuda - 401-413 Treatment Preferences of Adolescents and Young Adults with Depressive Symptoms: A Discrete Choice Experiment
by Ruth C. Waumans & Anna D. T. Muntingh & Jorien Veldwijk & Adriaan Hoogendoorn & Anton J. L. M. Balkom & Neeltje M. Batelaan - 415-426 Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
by Nidhi Gupta & Dharna Gupta & Kiran Gopal Vaska & Shankar Prinja
March 2024, Volume 22, Issue 2
- 129-130 Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses
by Jonathan Karnon & Clarabelle Pham - 131-144 Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations
by Bethany Shinkins & A. Joy Allen & James Karichu & Louis P. Garrison & Brigitta U. Monz - 145-154 Participatory Value Evaluation (PVE): A New Preference-Elicitation Method for Decision Making in Healthcare
by Sander Boxebeld & Niek Mouter & Job Exel - 155-164 An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone
by Aidan Hollis - 165-179 The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review
by Philipp Weber & Leonie Birkholz & Riccarda Straub & Simone Kohler & Natalie Helsper & Lea Dippon & Klaus Pfeifer & Alfred Rütten & Jana Semrau - 181-192 Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review
by Akhil Sasidharan & Bhavani Shankara Bagepally & S Sajith Kumar - 193-207 Should Commercial Diagnostic Testing Be Stimulated or Discouraged? Analyzing Willingness-to-Pay and Market Externalities of Three Commercial Diagnostic Tests in The Netherlands
by Niek Stadhouders & Ella Vliet & Anne E.M. Brabers & Wieteke Dijk & Suzanne Onstwedder - 209-225 Do Informal Care Recipients Internalise Carer Burden? Examining the Impact of Informal Care Receipt on Health Behaviours
by Jack Elliott & Igor Francetic & Rachel Meacock & Matt Sutton - 227-242 Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L
by Xin Zhang & Karin M. Vermeulen & Paul F. M. Krabbe - 243-254 Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation
by Janet Bouttell & Heather Fraser & John R. Goodlad & David Hopkins & Pam McKay & Karin A. Oien & Bruce Seligmann & Stephan Delft & Neil Hawkins - 255-264 Health Service Utilisation of People Living with Psychosis: Validity of Self-report Compared with Administrative Data in a Randomised Controlled Trial
by Vergil Dolar & Mary Lou Chatterton & Long Khanh-Dao Le & Cathrine Mihalopoulos & Neil Thomas & Lidia Engel - 265-267 Comment on: “Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses”
by Natalia Kunst & Annisa Siu & Michael Drummond & Sabine Grimm & Janneke Grutters & Don Husereau & Hendrik Koffijberg & Claire Rothery & Edward C. F. Wilson & Anna Heath - 269-269 Correction to: Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L
by Xin Zhang & Karin M. Vermeulen & Paul F. M. Krabbe - 271-272 Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance
by Jake T. W. Williams & Katy J. L. Bell & Rachael L. Morton & Mbathio Dieng
January 2024, Volume 22, Issue 1
- 5-7 The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA
by Lindsay Allen - 9-16 Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation
by Becky Pennington & Hareth Al-Janabi - 17-32 A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana
by Aashima & Rajesh Sharma - 33-48 Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
by Yan Li & Pingyu Chen & Xintian Wang & Qian Peng & Shixia Xu & Aixia Ma & Hongchao Li - 49-60 Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom
by Max Kindred & Zahratu Shabrina & Neily Zakiyah - 61-71 Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older
by Shoroq M. Altawalbeh & Angela R. Wateska & Mary Patricia Nowalk & Chyongchiou J. Lin & Lee H. Harrison & William Schaffner & Richard K. Zimmerman & Kenneth J. Smith - 73-84 Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy
by Constanza Vargas & Rebecca Addo & Milena Lewandowska & Philip Haywood & Richard Abreu Lourenco & Stephen Goodall - 85-95 Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
by Rui Li & Pengyi Lu & Christopher K. Fairley & José A. Pagán & Wenyi Hu & Qianqian Yang & Guihua Zhuang & Mingwang Shen & Yan Li & Lei Zhang - 97-106 VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives
by Elizabeta Ribarić & Ismar Velić & Ana Bobinac - 107-122 Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia
by Martin Vu & Koen Degeling & Ella R. Thompson & Piers Blombery & David Westerman & Maarten J. IJzerman - 123-124 Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”
by Sieta T. Vries & Noral Huda S. Al-Mugoter & Irena Petkoska & Stefan Verweij & André J. A. Elferink & Peter G. M. Mol - 125-126 Comment on: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”
by Afschin Gandjour - 127-128 Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”
by Melanie Büssgen & Tom Stargardt
November 2023, Volume 21, Issue 6
- 823-830 Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?
by Tracy Merlin & Jackie Street & Drew Carter & Hossein Haji Ali Afzali - 831-840 Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
by Karel H. Pol & Mohamad Aljofan & Olivier Blin & Jan H. Cornel & Gerard A. Rongen & Aurélie-Gaëlle Woestelandt & Michael Spedding - 841-855 Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for Cancer: A Systematic Review
by Sibo Liu & Daniel SW Tan & Nicholas Graves & Ann-Marie Chacko - 857-875 Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies
by Yi Jing Tan & Siew Chin Ong & Ying Min Kan - 877-889 Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–2040
by Marta Ortega-Ortega & Paul Hanly & Alison Pearce & Isabelle Soerjomataram & Linda Sharp - 891-903 Evaluating the Short-Term Costs and Benefits of a Nationwide Diabetes Prevention Programme in England: Retrospective Observational Study
by Emma McManus & Rachel Meacock & Beth Parkinson & Matt Sutton - 905-914 Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
by Aniek Dane & Anne-Sophie Klein Gebbink & Jan-Dietert Brugma & Albane Degrassat-Théas & Martin J. Hug & Morten B. Houlind & P. Paubel & P. Hugo M. Kuy & Carin A. Uyl-de Groot - 915-924 Direct Medical Costs of COPD in the USA: An Analysis of the Medical Expenditure Panel Survey 2017–2018
by Chintal H. Shah & Robert M. Reed & Linda Wastila & Eberechukwu Onukwugha & Mathangi Gopalakrishnan & Zafar Zafari - 925-935 The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022
by Michela Meregaglia & Francesco Malandrini & Stefania Angelini & Oriana Ciani - 937-947 Child–Parent Agreement in the Assessment of Health-Related Quality of Life Using the CHU9D and the PedsQLTM
by Diana Khanna & Jyoti Khadka & Christine Mpundu-Kaambwa & Julie Ratcliffe - 949-965 Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions
by Rakhee Raghunandan & Kirsten Howard & Sarah Smith & Anagha Killedar & Erin Cvejic & Martin Howell & Stavros Petrou & Emily Lancsar & Germaine Wong & Jonathan Craig & Alison Hayes - 967-967 Correction: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?
by Howard Thom
September 2023, Volume 21, Issue 5
- 683-687 Health Reform in Aotearoa New Zealand: Insights on Health Equity Challenges One Year On
by Paula K. Lorgelly & Daniel J. Exeter - 689-700 myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
by Heather Davies & Mary Chappell & Yingying Wang & Angaja Phalguni & Stephanie Wake & Mick Arber & Judith Shore - 701-717 A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?
by Rajani Pokharel & Yi-Shu Lin & Ethna McFerran & James F. O’Mahony - 719-730 The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates
by Varsha Shukla & Rahul Arora - 731-750 Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models
by Ali Ahmed & Juman Abdulelah Dujaili & Lay Hong Chuah & Furqan Khurshid Hashmi & Long Khanh-Dao Le & Saval Khanal & Ahmed Awaisu & Nathorn Chaiyakunapruk - 751-759 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
by Melanie Büssgen & Tom Stargardt - 761-771 Symptomatic SARS-CoV-2 Episodes and Health-Related Quality of Life
by Caterina Alacevich & Inna Thalmann & Catia Nicodemo & Simon Lusignan & Stavros Petrou - 773-783 Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis
by Weijia Wu & Yuping Zhou & Yannan Wang & Syed Afroz Keramat & Namal N. Balasooriya & Zixuan Zhao & Yi Yang & Tracy Comans & Hengjin Dong - 785-797 Preferences for Enhanced Primary Care Services Among Older Individuals and Primary Care Physicians
by Semra Ozdemir & John Ansah & David Matchar - 799-811 What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France
by Marion Tano & Pascal Paubel & Matthieu Ribault & Albane Degrassat-Théas - 813-820 Values in Modelling: Video Series Development and Evaluation Survey
by Stephanie Harvard & Adam Easterbrook & Greg Werker & Alison McLean & Amin Adibi & David Murphy - 821-821 Correction to: The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory
by Richard M. Wood & Alison L. Harper & Zehra Onen-Dumlu & Paul G. Forte & Martin Pitt & Christos Vasilakis
July 2023, Volume 21, Issue 4
- 533-535 Health technology assessment – an important opportunity to inform the use of medical devices in the paediatric population: an analysis of NICE Medical Technology Guidance
by Sarah Greasley & Mark Campbell & James Wall - 537-546 Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
by Christopher H. Henshall & Dávid Dankó & Leela Barham & Jaime Espín & Jorge Felix & Mary Harney & Peter Indra & Jorge Mestre-Ferrandiz & Gérard Pouvourville & Federico Spandonaro & Luka Vončina & Nils Wilking - 547-558 How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
by Matthew Franklin & Colin Angus & Tobias Welte & Guy Joos - 559-584 Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments
by Joseph Kwon & Sarah Smith & Rakhee Raghunandan & Martin Howell & Elisabeth Huynh & Sungwook Kim & Thomas Bentley & Nia Roberts & Emily Lancsar & Kirsten Howard & Germaine Wong & Jonathan Craig & Stavros Petrou - 585-601 Modelling Methods of Economic Evaluations of HIV Testing Strategies in Sub-Saharan Africa: A Systematic Review
by Arthi Vasantharoopan & Victoria Simms & Yuyen Chan & Lorna Guinness & Hendramoorthy Maheswaran - 603-614 Public Preferences for Introducing a COVID-19 Certificate: A Discrete Choice Experiment in the Netherlands
by J. Veldwijk & J. Exel & E. W. Bekker-Grob & N. Mouter - 615-625 Modelled Distributional Cost-Effectiveness Analysis of Childhood Obesity Interventions: A Demonstration
by Anagha Killedar & Thomas Lung & Rachael W. Taylor & Alison Hayes - 627-635 A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
by Afschin Gandjour - 637-650 Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections in Argentina
by Alfredo Palacios & Federico Rodriguez-Cairoli & Dario Balan & Carlos Rojas-Roque & Carolina Moreno-López & Barbara Braun & Federico Augustovski & Andrés Pichon-Riviere & Ariel Bardach - 651-659 Exploring Consumer Preferences for Cannabis Vaping Products to Support Public Health Policy: A Discrete Choice Experiment
by Jennifer R. Donnan & Karissa Johnston & Michael Coombs & Maisam Najafizada & Lisa D. Bishop - 661-672 Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
by Jaesh Naik & Norma Beavers & Fredrik O. L. Nilsson & Laura Iadeluca & Chrissy Lowry - 673-681 Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis
by Pooyeh Graili
May 2023, Volume 21, Issue 3
- 361-364 Global Pull Incentives for Better Antibacterials: The UK Leads the Way
by Kevin Outterson & John H. Rex - 365-372 Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?
by Colm Leonard & Nick Crabb & David Glover & Sophie Cooper & Jacoline Bouvy & Milena Wobbe & Mark Perkins - 373-384 The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework
by Laura Vallejo-Torres - 385-394 An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology
by Holly L. Cranmer & Gemma E. Shields & Ash Bullement - 395-403 Stakeholder Engagement in the Development of Public Health Economic Models: An Application to Modelling of Minimum Unit Pricing of Alcohol in South Africa
by N. K. Gibbs & C. Angus & S. Dixon & C. D. H. Parry & P. S. Meier - 405-418 Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends
by Haode Wang & Donna L. Rowen & John E. Brazier & Litian Jiang - 419-440 A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America
by Carlos Rojas-Roque & Alfredo Palacios - 441-466 The Impact of Value-Based Payment Models for Networks of Care and Transmural Care: A Systematic Literature Review
by Diogo L. L. Leao & Henricus-Paul Cremers & Dennis Veghel & Milena Pavlova & Wim Groot - 467-475 Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review
by Sean Docking & Lan Gao & Zanfina Ademi & Christian Bonello & Rachelle Buchbinder - 477-487 Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data
by Johannes Wendl & Andreas Simon & Martin Kistler & Jana Hapfelmeier & Antonius Schneider & Alexander Hapfelmeier - 489-499 Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis
by Yawen Jiang & Shan Jiang & Limin Li & Si Shi & Mincai Li & Lei Si - 501-510 The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment
by Meghan McGee & Kellia Chiu & Rahim Moineddin & Abhimanyu Sud - 511-522 Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand
by Waranya Rattanavipapong & Chittawan Poonsiri & Wanrudee Isaranuwatchai & Sopon Iamsirithaworn & Jutarat Apakupakul & Chaninan Sonthichai & Rungrueng Kitphati & Yot Teerawattananon - 523-532 Measurement of Health-Related Quality of Life from Conception to Postpartum Using the EQ-5D-5L Among a National Sample of US Pregnant and Postpartum Adults
by Annette K. Regan & Pallavi Aytha Swathi & Marcianna Nosek & Ning Yan Gu
March 2023, Volume 21, Issue 2
- 155-166 Development of an Instrument for the Assessment of Health-Related Multi-sectoral Resource Use in Europe: The PECUNIA RUM
by Irina Pokhilenko & Luca M. M. Janssen & Aggie T. G. Paulus & Ruben M. W. A. Drost & William Hollingworth & Joanna C. Thorn & Sian Noble & Judit Simon & Claudia Fischer & Susanne Mayer & Luis Salvador-Carulla & Alexander Konnopka & Leona Hakkaart van Roijen & Valentin Brodszky & A-La Park & Silvia M. A. A. Evers - 167-193 The Role of Mental Health on Workplace Productivity: A Critical Review of the Literature
by Claire Oliveira & Makeila Saka & Lauren Bone & Rowena Jacobs - 195-204 Headroom Analysis for Early Economic Evaluation: A Systematic Review
by Esther A. Boudewijns & Thomas M. Otten & Mariam Gobianidze & Bram L. Ramaekers & Onno C. P. Schayck & Manuela A. Joore - 205-224 Analysing the Efficiency of Health Systems: A Systematic Review of the Literature
by Rahab Mbau & Anita Musiega & Lizah Nyawira & Benjamin Tsofa & Andrew Mulwa & Sassy Molyneux & Isabel Maina & Julie Jemutai & Charles Normand & Kara Hanson & Edwine Barasa - 225-242 The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review
by Andrew Gallagher & Violetta Shersher & Duncan Mortimer & Helen Truby & Terry Haines - 243-251 The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory
by Richard M. Wood & Alison L. Harper & Zehra Onen-Dumlu & Paul G. Forte & Martin Pitt & Christos Vasilakis - 253-262 A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis
by Ross Wilson & Yana Pryymachenko & J. Haxby Abbott & Sarah Dean & James Stanley & Sue Garrett & Fiona Mathieson & Anthony Dowell & Ben Darlow - 263-273 An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials
by Chris Schilling & Michelle Tew & Samantha Bunzli & Cade Shadbolt & L. Stefan Lohmander & Zsolt J. Balogh & Francesco Paolucci & Peter F. Choong & Michelle M. Dowsey & Philip Clarke - 275-287 Population-Level Impact of Omitting Axillary Lymph Node Dissection in Early Breast Cancer Women: Evidence from an Economic Evaluation in Germany
by Hoa Thi Nguyen & Manuela Allegri & Jörg Heil & André Hennigs - 289-303 EQ-5D-5L Population Norms for Italy
by Michela Meregaglia & Francesco Malandrini & Aureliano Paolo Finch & Oriana Ciani & Claudio Jommi - 305-314 The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals
by Patricia G. Synnott & Dominic Voehler & Daniel E. Enright & Stacey Kowal & Daniel A. Ollendorf - 315-325 Cost-Effectiveness and Value of Information Analysis of an Ambient Intelligent Geriatric Management (AmbIGeM) System Compared to Usual Care to Prevent Falls in Older People in Hospitals
by Clarabelle T. Pham & Renuka Visvanathan & Mark Strong & Edward C. F. Wilson & Kylie Lange & Joanne Dollard & Damith Ranasinghe & Keith Hill & Anne Wilson & Jonathan Karnon - 327-346 An Item-Response Mapping from General Health Questionnaire Responses to EQ-5D-3L Using a General Population Sample from England
by Edward J. D. Webb - 347-359 A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England
by Iyn-Hyang Lee & Karen Bloor & Eun-Young Bae
January 2023, Volume 21, Issue 1
- 5-10 Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?
by Ashley A. Leech & Pei-Jung Lin & Brittany D’Cruz & Susan K. Parsons & Tara A. Lavelle - 11-22 Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India
by Yashika Chugh & Pankaj Bahuguna & Aamir Sohail & Kavitha Rajsekar & V. R. Muraleedharan & Shankar Prinja - 23-30 Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance
by Jake T. W. Williams & Katy J. L. Bell & Rachael L. Morton & Mbathio Dieng - 31-38 Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon
by Jalal Dahham & Ingrid Kremer & Mickaël Hiligsmann & Kamal Hamdan & Abdallah Nassereddine & Silvia M. A. A. Evers & Rana Rizk - 39-51 A Systematic Review of Kidney Transplantation Decision Modelling Studies
by Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan - 53-70 Economic Evaluations of Preventive Interventions for Dental Caries and Periodontitis: A Systematic Review
by Tan Minh Nguyen & Utsana Tonmukayakul & Long Khanh-Dao Le & Hanny Calache & Cathrine Mihalopoulos - 71-89 Determinants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes
by Pragyan Deb & Davide Furceri & Daniel Jimenez & Siddharth Kothari & Jonathan D. Ostry & Nour Tawk - 91-107 What Features of Fertility Treatment do Patients Value? Price Elasticity and Willingness-to-Pay Values from a Discrete Choice Experiment
by Elena Keller & Willings Botha & Georgina M. Chambers - 109-118 Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients
by Anna-Katharina Böhm & Udo Schneider & Tom Stargardt - 119-130 Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis
by Christian Domingo & Mario Fernandez & Noe Garin & Javier Milara & Ignacio Moran & Irantzu Muerza & Adalberto Pacheco & Carlos Teruel & Roy Bentley & Rafael Subiran & Alicia Gil - 131-140 Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective
by Pankaj Bahuguna & Emiko Masaki & Gursimer Jeet & Shankar Prinja - 141-152 Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis
by Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh - 153-153 Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis
by Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh
November 2022, Volume 20, Issue 6
- 783-792 Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies
by Daniel Howdon & Sebastian Hinde & James Lomas & Matthew Franklin - 793-802 Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study
by Sebastian Hinde & Dan Howdon & James Lomas & Matthew Franklin - 803-817 Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
by Yannick Vandenplas & Steven Simoens & Florian Turk & Arnold G. Vulto & Isabelle Huys - 819-834 Systematic Review and Quality Assessment of Health Economic Evaluation Studies (2007–2019) Conducted in South Korea
by Sunghyun Yi & Jihyung Hong & Haemin Yoon & You-na Lim & Eun-Young Bae - 835-843 Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance
by Sofie Larsson & Charlotta Edlund & Pontus Nauclér & Mikael Svensson & Anders Ternhag - 845-856 Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
by Ze Cong & Oth Tran & James Nelson & Monica Silver & Karen Chung - 857-866 Evaluating Health Inequality in Five Caribbean Basin Countries Using EQ-5D-5L
by Henry H. Bailey & Mathieu F. Janssen & Fareena M. Alladin & Althea Foucade & Rodrigo Varela & Jhon A. Moreno & Marjorie Wharton & Philip Castillo & Girjanauth Boodraj - 867-880 Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach
by Bettina Wulff Risør & Nasrin Tayyari Dehbarez & Jacob Fredsøe & Karina Dalsgaard Sørensen & Bodil Ginnerup Pedersen - 881-891 Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach
by Silvia Moler-Zapata & Noémi Kreif & Jessica Ochalek & Andrew J. Mirelman & Mardiati Nadjib & Marc Suhrcke - 893-904 Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China
by Ziping Ye & Raela Abduhilil & Jiaxin Huang & Lihua Sun - 905-917 Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis
by Caroline S. Clarke & Mariya Melnychuk & Angus I. G. Ramsay & Cecilia Vindrola-Padros & Claire Levermore & Ravi Barod & Axel Bex & John Hines & Muntzer M. Mughal & Kathy Pritchard-Jones & Maxine Tran & David C. Shackley & Stephen Morris & Naomi J. Fulop & Rachael M. Hunter
September 2022, Volume 20, Issue 5
- 625-628 Including Pharmaceuticals in Bundled Payments
by Gerard F. Anderson & Andrew York & Joshua L. Choe - 629-635 Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)
by Emma Frew & Nafsika Afentou & Hamideh Mohtashami Borzadaran & Paolo Candio & Irina Pokhilenko - 637-650 Centralised Pharmaceutical Procurement: Learnings from Six European Countries
by Sabine Vogler & Eveli Bauer & Katharina Habimana - 651-667 Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
by Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse - 669-680 UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
by Laura Knight & Megan Dale & Andrew Cleves & Charlotte Pelekanou & Rhys Morris - 681-691 An Economic Evaluation of Government-Funded COVID-19 Testing in Australia
by Jonathan Karnon & Hossein Haji Ali Afzali & Billie Bonevski - 693-706 Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians
by Jeremy Fabes & Tuba Saygın Avşar & Jonathan Spiro & Thomas Fernandez & Helge Eilers & ·Steve Evans & Amelia Hessheimer & Paula Lorgelly & Michael Spiro - 707-716 Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi
by Fulgence Niyibitegeka & Montarat Thavorncharoensap & Arthorn Riewpaiboon & Sitaporn Youngkong - 717-729 Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
by Renée E. Michels & Carlos H. Arteaga & Michel L. Peters & Ellen Kapiteijn & Carla M. L. Herpen & Marieke Krol - 731-742 ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
by Kristyna Lacinova & Praveen Thokala & Richard Nicholas & Pamela Dobay & Erik Scalfaro & Zuzanna Angehrn & Roisin Brennan & Ibolya Boer & Carol Lines & Nicholas Adlard - 743-755 Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
by Jia Liu & Xiaoning He & Jing Wu - 757-768 Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
by Daniel Tobias Michaeli & Mackenzie Mills & Panos Kanavos - 769-779 Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia
by Sameera Senanayake & Helen Healy & Steven M. McPhail & Keshwar Baboolal & Sanjeewa Kularatna - 781-782 Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska
July 2022, Volume 20, Issue 4
- 453-455 Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
by Livio Garattini & Bruno Finazzi - 457-465 Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines
by Jamison Pike & Andrew J. Leidner & Harrell Chesson & Charles Stoecker & Scott D. Grosse - 467-477 Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
by Eun-Young Bae & Jihyung Hong & SeungJin Bae & Seokyung Hahn & Hyonggin An & Eun-joo Hwang & Seung-min Lee & Tae-jin Lee - 479-486 Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy
by Nadine T. Hillock & Tracy L. Merlin & John Turnidge & Jonathan Karnon - 487-499 A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis
by Edyta Ryczek & Susan C. Peirce & Laura Knight & Andrew Cleves & Andrew Champion & Iolo Doull & Sian Lewis - 501-524 Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
by Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apostolos Tsiachristas - 525-541 What Policy Approaches Were Effective in Reducing Catastrophic Health Expenditure? A Systematic Review of Studies from Multiple Countries
by HyunWoo Jung & Kwang-Soo Lee - 543-555 Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu - 557-572 How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15
by Stephen Martin & Karl Claxton & James Lomas & Francesco Longo - 573-585 Population Norms for SF-6Dv2 and EQ-5D-5L in China
by Shitong Xie & Jing Wu & Feng Xie - 587-596 Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand
by Piyameth Dilokthornsakul & Ratree Sawangjit & Pisit Tangkijvanich & Maneerat Chayanupatkul & Tawesak Tanwandee & Wattana Sukeepaisarnjaroen & Pajaree Sriuttha & Unchalee Permsuwan - 597-607 Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment
by Andrea N. Natsky & Andrew Vakulin & Ching Li Chai-Coetzer & R. Doug McEvoy & Robert J. Adams & Billingsley Kaambwa - 609-621 Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women
by Nidhi Gupta & Dharna Gupta & Jyoti Dixit & Nikita Mehra & Ashish Singh & Manjunath Nookala Krishnamurthy & Gaurav Jyani & Kavitha Rajsekhar & Jayachandran Perumal Kalaiyarasi & Partha Sarathi Roy & Prabhat Singh Malik & Anisha Mathew & Pankaj Malhotra & Sudeep Gupta & Lalit Kumar & Amal Kataki & Shankar Prinja - 623-623 Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu
May 2022, Volume 20, Issue 3
- 287-290 How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
by Charalabos-Markos Dintsios & Nadja Chernyak - 291-303 Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
by Sándor Kovács & Bertalan Németh & Dalma Erdősi & Valentin Brodszky & Imre Boncz & Zoltán Kaló & Antal Zemplényi - 305-313 Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
by Ruth Louise Poole & Megan Dale & Helen Morgan & Tosin Oladapo & Rebecca Brookfield & Rhys Morris - 315-335 A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa
by Mouaddh Abdulmalik Nagi & Pramitha Esha Nirmala Dewi & Montarat Thavorncharoensap & Sermsiri Sangroongruangsri - 337-349 Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries
by Laura Vallejo-Torres & Borja García-Lorenzo & Laura Catherine Edney & Niek Stadhouders & Ijeoma Edoka & Iván Castilla-Rodríguez & Lidia García-Pérez & Renata Linertová & Cristina Valcárcel-Nazco & Jonathan Karnon - 351-370 Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review
by Jiayu Shi & Kenan Fan & Lei Yan & Zijuan Fan & Fei Li & Guishan Wang & Haifeng Liu & Peidong Liu & Hongmei Yu & Jiao Jiao Li & Bin Wang - 371-381 Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India
by V. Srinivasan & David E. Bloom & Alex Khoury - 383-393 Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents
by Mimmi Åström & Ola Rolfson & Kristina Burström